P2Y1 receptor in Alzheimer’s disease

Alzheimer’s disease is the most frequent form of dementia characterized by the deposition of amyloid-beta plaques and neurofibrillary tangles consisting of hyperphosphorylated tau.Targeting amyloid-beta plaques has been a primary direction for developing Alzheimer’s disease treatments in the last decades.However,existing drugs targeting amyloid-beta plaques have not fully yielded the expected results in the clinic,necessitating the exploration of alternative therapeutic strategies.Increasing evidence unravels that astrocyte morphology and function alter in the brain of Alzheimer’s disease patients,with dysregulated astrocytic purinergic receptors,particularly the P2Y1 receptor,all of which constitute the pathophysiology of Alzheimer’s disease.These receptors are not only crucial for maintaining normal astrocyte function but are also highly implicated in neuroinflammation in Alzheimer’s disease.This review delves into recent insights into the association between P2Y1 receptor and Alzheimer’s disease to underscore the potential neuroprotective role of P2Y1 receptor in Alzheimer’s disease by mitigating neuroinflammation,thus offering promising avenues for developing drugs for Alzheimer’s disease and potentially contributing to the development of more effective treatments.

The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity:A Meta-Analysis

Objective Recent studies have indicated potential anti-inflammatory effects of glucagon-like peptide-1 receptor agonists(GLP-1RAs)on asthma,which is often comorbid with type 2 diabetes mellitus(T2DM)and obesity.Therefore,we conducted a meta-analysis to assess the association between the administration of glucagon-like peptide-1(GLP-1)receptor-based agonists and the incidence of asthma in patients with T2DM and/or obesity.Methods PubMed,Web of Science,Embase,the Cochrane Central Register of Controlled Trials,and Clinicaltrial.gov were systematically searched from inception to July 2023.Randomized controlled trials(RCTs)of GLP-1 receptor-based agonists(GLP-1RA,GLP-1 based dual and triple receptor agonist)with reports of asthma events were included.Outcomes were computed as risk ratios(RR)using a fixedeffects model.Results Overall,39 RCTs with a total of 85,755 participants were included.Compared to non-GLP-1 receptor-based agonist users,a trend of reduced risk of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments,although the difference was not statistically significant[RR=0.91,95%confidence interval(CI):0.68 to 1.24].Further Subgroup analyses indicated that the use of light-molecular-weight GLP-1RAs might be associated with a reduced the risk of asthma when compared with non-users(RR=0.65,95%CI:0.43 to 0.99,P=0.043).We also performed sensitivity analyses for participant characteristics,study design,drug structure,duration of action,and drug subtypes.However,no significant associations were observed.Conclusion Compared with non-users,a modest reduction in the incidence of asthma was observed in patients with T2DM or obesity using GLP-1 receptor-based agonist treatments.Further investigations are warranted to assess the association between GLP-1 receptor-based agonists and the risk of asthma.

Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes:A systematic review with multiple network meta-regressions

BACKGROUND Glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are associated with significant cardiovascular benefit in type 2 diabetes(T2D).However,GLP-1RA or SGLT-2I alone may not improve some cardiovascular outcomes in patients with prior cardiovascular co-morbidities.AIM To explore whether combining GLP-1RA and SGLT-2I can achieve additional benefit in preventing cardiovascular diseases in T2D.METHODS The systematic review was conducted according to PRISMA recommendations.The protocol was registered on PROSPERO(ID:42022385007).A total of 107049 participants from eligible cardiovascular outcomes trials of GLP-1RA and SGLT-2I were included in network meta-regressions to estimate cardiovascular benefit of the combination treatment.Effect modification of prior myocardial infarction(MI)and heart failure(HF)was also explored to provide clinical insight as to when the INTRODUCTION The macro-and micro-vascular benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA)and sodium-glucose co-transporter-2 inhibitors(SGLT-2I)are independent of their glucose-lowering effects[1].In patients with type 2 diabetes(T2D),the major cardiovascular outcome trials(CVOT)showed that dipeptidyl peptidase-4 inhibitors(DPP-4I)did not improve cardiovascular outcomes[2],whereas cardiovascular benefit of GLP-1RA or SGLT-2I was significant[3,4].Further subgroup analyses indicated that the background cardiovascular risk should be considered when examining the cardiovascular outcomes of these newer glucose-lowering medications.For instance,prevention of major adverse cardiovascular events(MACE)was only seen in those patients with baseline atherosclerotic cardiovascular disease[3,4].Moreover,a series of CVOT conducted in patients with heart failure(HF)have demonstrated that(compared with placebo)SGLT-2I significantly reduced risk of hospitalization for HF or cardiovascular death,irrespective of their history of T2D[5-8].However,similar cardiovascular benefits were not observed in those with myocardial infarction(MI)[9,10].Cardiovascular co-morbidities are not only approximately twice as common but are also associated with dispropor-tionately worse cardiovascular outcomes in patients with T2D,compared to the general population[11].Therefore,it is of clinical importance to investigate whether the combination treatment of GLP-1RA and SGLT-2I could achieve greater cardiovascular benefit,particularly when considering patients with cardiovascular co-morbidities who may not gain sufficient cardiovascular protection from the monotherapies.This systematic review with multiple network meta-regressions was mainly aimed to explore whether combining GLP-1RA and SGLT-2I can provide additional cardiovascular benefit in T2D.Cardiovascular outcomes of these newer antidiabetic medications were also estimated under effect modification of prior cardiovascular diseases.This was to provide clinical insight as to when the combination treatment might be prioritized.

A Retrospective Analysis of Glucagon-Like Peptide 1 Receptor Agonists in Treating Type 2 Diabetes Mellitus Complicated by Nonalcoholic Fatty Liver Disease

Background: The objective of this study was to compare and analyze the variations in clinical indices before and after treatment of type 2 mellitus (T2DM) combined with nonalcoholic fatty liver disease (NAFLD) that were treated with glucagon-like peptide 1 receptor agonists (GLP-1RAs). Methods: The electronic medical record system was utilized to search for a total of 16 patients with type 2 diabetes complicated by NAFLD who were hospitalized at the First Affiliated Hospital of Yangtze University from October 2022 to April 2023 and treated with GLP-1RA for the first time. The clinical indices were compared before and after 12 weeks of treatment with GLP-1RA. Results: The liver-spleen CT ratio (L/S), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) in all patients treated with GLP-1RA after 12 weeks were significantly different (P 0.05). The patients were categorized into two groups based on the types of GLP-1RAs. The changes in L/S, TC, TG, and LDL-C in the long-acting group after treatment were statistically significant (P Conclusions: GLP-1RAs can improve liver function, regulate lipid metabolism, and reduce the severity of fatty liver in patients with T2DM complicated by NAFLD, which demonstrates the importance of clinical applications.

Interleukin-1 receptor associated kinase 2 is a functional downstream regulator of complement factor D that controls mitochondrial fitness in diabetic cardiomyopathy

Diabetic cardiomyopathy is a disorder of the cardiac muscle that affects patients with diabetes.The exact mechanisms underlying diabetic cardiomyopathy are mostly unknown,but several factors have been implicated in the pathogenesis of the disease and its progression towards heart failure,including endothelial dysfunction,autonomic neuropathy,metabolic alterations,oxidative stress,and alterations in ion homeostasis,especially calcium transients[1].In Military Medical Research,Jiang et al.[2]sought to determine the functional role of complement factor D(Adipsin)in the pathophysiology of diabetic cardiomyopathy.

Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer

BACKGROUND Patients with human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer have poor outcomes.Trastuzumab combined with chemotherapy is the first-line standard treatment for HER2-positive advanced gastric cancer.Inetetamab is a novel anti-HER2 drug,and its efficacy and safety in gastric cancer have not yet been reported.AIM To evaluate the efficacy and safety of the S-1 plus oxaliplatin(SOX)regimen combined with inetetamab as a first-line treatment for HER2-positive advanced gastric cancer.METHODS Thirty-eight patients with HER2-positive advanced gastric cancer or gastroeso-phageal junction adenocarcinoma were randomly divided into two groups:One group received inetetamab combined with the SOX regimen,and the other group received trastuzumab combined with the SOX regimen.After 4-6 cycles,patients with stable disease received maintenance therapy.The primary endpoints were progression-free survival(PFS)and overall survival(OS),and the secondary endpoints were the objective response rate,disease control rate,and adverse events(AEs).RESULTS Thirty-seven patients completed the trial,with 18 patients in the inetetamab group and 19 patients in the trastuzumab group.In the inetetamab group,the median PFS was 8.5 months,whereas it was 7.3 months in the trastuzumab group(P=0.046);this difference was significant.The median OS in the inetetamab group vs the trastuzumab group was 15.4 months vs 14.3 months(P=0.33),and the objective response rate was 50%vs 42%(P=0.63),respectively;these differences were not significant.Common AEs included leukopenia,thrombocytopenia,nausea,and vomiting.The incidence rates of grade≥3 AEs were 56%in the inetetamab group and 47%in the trastuzumab group(P=0.63),with no significant difference.CONCLUSION In the first-line treatment of HER2-positive advanced gastric cancer,inetetamab and trastuzumab showed comparable efficacy.The inetetamab group showed superior PFS,and both groups had good safety.

Accurate Diagnosis of SARS-CoV-2 JN.1 by Sanger Sequencing of Receptor-Binding Domain Is Needed for Clinical Evaluation of Its Immune Evasion

Background: Omicron JN.1 has become the dominant SARS-CoV-2 variant in recent months. JN.1 has the highest number of amino acid mutations in its receptor binding domain (RBD) and has acquired a hallmark L455S mutation. The immune evasion capability of JN.1 is a subject of scientific investigation. The US CDC used SGTF of TaqPath COVID-19 Combo Kit RT-qPCR as proxy indicator of JN.1 infections for evaluation of the effectiveness of updated monovalent XBB.1.5 COVID-19 vaccines against JN.1 and recommended that all persons aged ≥ 6 months should receive an updated COVID-19 vaccine dose. Objective: Recommend Sanger sequencing instead of proxy indicator to diagnose JN.1 infections to generate the data based on which guidelines are made to direct vaccination policies. Methods: The RNA in nasopharyngeal swab specimens from patients with clinical respiratory infection was subjected to nested RT-PCR, targeting a 398-base segment of the N-gene and a 445-base segment of the RBD of SARS-CoV-2 for amplification. The nested PCR amplicons were sequenced. The DNA sequences were analyzed for amino acid mutations. Results: The N-gene sequence showed R203K, G204R and Q229K, the 3 mutations associated with Omicron BA.2.86 (+JN.1). The RBD sequence showed 24 of the 26 known amino acid mutations, including the hallmark L455S mutation for JN.1 and the V483del for BA.2.86 lineage. Conclusions: Sanger sequencing of a 445-base segment of the SARS-CoV-2 RBD is useful for accurate determination of emerging variants. The CDC may consider using Sanger sequencing of the RBD to diagnose JN.1 infections for statistical analysis in making vaccination policies.

Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards

This editorial is stimulated by the article by Alqifari et al published in the World Journal of Diabetes(2024).Alqifari et al focus on practical advice for the clinical use of glucagon-like-peptide-1(GLP-1)receptor agonists(GLP-1RAs)in the management of type 2 diabetes and this editorial provides complementary information.We initially give a brief historical perspective of the development of GLP-1RAs stimulated by recognition of the‘incretin effect’,the substantially greater insulin increase to enteral when compared to euglycaemic intravenous glucose,and the identification of the incretin hormones,GIP and GLP-1.In addition to stimulating insulin,GLP-1 reduces postprandial glucose levels by slowing gastric emptying.GLP-1RAs were developed because native GLP-1 has a very short plasma half-life.The majority of current GLP-1RAs are administered by subcutaneous injection once a week.They are potent in glucose lowering without leading to hypoglycaemia,stimulate weight loss in obese individuals and lead to cardiovascular and renal protection.The landscape in relation to GLP-1RAs is broadening rapidly,with different formulations and their combination with other peptides to facilitate both glucose lowering and weight loss.There is a need for more information relating to the effects of GLP-1RAs to induce gastrointestinal symptoms and slow gastric emptying which is likely to allow their use to become more effective and personalised.

姜酮通过激活Nrf2/HO-1信号通路减轻OGD/R后氧化应激损伤对HT22细胞凋亡的抑制作用

目的:探讨姜酮对氧糖剥夺/复糖复氧(OGD/R)后小鼠海马神经元HT22细胞的保护作用,阐明其相关作用机制。方法:培养HT22细胞,设置不同OGD/R时间梯度,建立OGD/R细胞损伤模型。HT22细胞分为对照组、OGD/R组、OGD/R+1μmol·L^(-1)姜酮组、OGD/R+10μmol·L^(-1)姜酮、OGD/R+100μmol·L^(-1)姜酮组和OGD/R+0.2%二甲亚枫(DMSO)组,CCK-8法检测各组细胞活性并计算各组细胞存活率,确定姜酮最适药物浓度。细胞分为对照组、OGD/R组、OGD/R+姜酮组和OGD/R+姜酮+核因子E2相关因子2(Nrf2)抑制剂(ML385)组,OGD/R+姜酮组细胞经姜酮给药处理4 h后予以OGD 8 h和复糖复氧8 h处理,OGD/R+姜酮+ML385组细胞在姜酮给药前予以10μmol·L^(-1)ML385预处理6 h,CCK-8法检测各组细胞活性,Western blotting法检测各组细胞中Nrf2、血红素加氧酶1(HO-1)、B细胞淋巴瘤2(Bcl-2)和Bcl-2相关X蛋白(Bax)蛋白表达水平,酶联免疫吸附试验(ELISA)法检测各组细胞培养上清中超氧化物歧化酶(SOD)活性和丙二醛(MDA)水平。结果:与对照组比较,HT22细胞经OGD 8 h和复糖复糖8 h处理后细胞存活率低于50%,以OGD 8 h和复糖复糖8 h建立HT22细胞OGD/R模型。与OGD/R组比较,OGD/R+不同剂量姜酮组细胞存活率均不同程度升高,其中OGD/R+100μmol·L^(-1)姜酮组细胞存活率升高最明显(P<0.01),故选用100μmol·L^(-1)姜酮用于后续实验。与对照组比较,OGD/R组细胞活性明显降低(P<0.01),细胞中Nrf2、HO-1和Bax蛋白表达水平明显升高(P<0.01),Bcl-2蛋白表达水平明显降低(P<0.05),细胞培养上清中SOD活性明显降低(P<0.01),MDA水平明显升高(P<0.01);与OGD/R组比较,OGD/R+姜酮组细胞活性明显升高(P<0.01),细胞中Nrf2、HO-1和Bcl-2蛋白表达水平明显升高(P<0.05或P<0.01),Bax蛋白表达水平明显降低(P<0.05),细胞培养上清中SOD活性明显升高(P<0.01),MDA水平明显降低(P<0.01);与OGD/R+姜酮组比较,OGD/R+姜酮+ML385组细胞活性明显降低(P<0.01),细胞中Nrf2、HO-1和Bcl-2蛋白表达水平明显降低(P<0.01),Bax蛋白表达水平明显升高(P<0.01),细胞培养上清中SOD活性明显降低(P<0.01),MDA水平明显升高(P<0.05)。结论:姜酮可通过激活Nrf2/HO-1信号通路减轻OGD/R后氧化应激损伤对HT22细胞凋亡的抑制作用。

葛根芩连汤通过IRS-1/PI3K/AKT通路对胃肠湿热型2型糖尿病大鼠糖脂代谢的影响

目的探究葛根芩连汤通过胰岛素受体底物-1(IRS-1)/磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(AKT)通路对胃肠湿热型2型糖尿病大鼠糖脂代谢的影响。方法将40只SD大鼠随机分为正常组(2 mL生理盐水灌胃)、造模组(2 mL生理盐水灌胃)、二甲双胍组(4.17 mg/100 g二甲双胍灌胃)和葛根芩连汤组(1 g/100 g葛根芩连汤灌胃),每组10只。采用高脂高糖饲料加腹腔注射链脲佐菌素(STZ)构建2型糖尿病大鼠模型,随后喂食油脂、42°白酒及蜂蜜水构建胃肠湿热型2型糖尿病大鼠模型。测量各组大鼠不同时间节点体质量,血糖仪测定空腹血糖(FBG);ELISA检测空腹胰岛素(FINS)、三酰甘油(TG)、总胆固醇(TC)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平变化、计算胰岛素抵抗指数(HOMA-IR);HE染色检测肝组织病理学变化;检测肝组织过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)及丙二醛(MDA)含量变化。Western blot检测肝组织IRS-1、PI3K、p-PI3K、AKT及p-AKT蛋白变化。结果与正常组比较,造模组大鼠体质量、FBG、FINS及HOMA-IR、GSH-Px、CAT、SOD、IRS-1、p-PI3K/PI3K及p-AKT/AKT水平均明显下降(P<0.05)、TG、TC、IL-6、TNF-α及MDA含量均显著升高(P<0.05),可见局灶性肝实质损失。与造模组比较,二甲双胍组及葛根芩连汤组大鼠体质量、FBG、FINS及HOMA-IR、GSH-Px、CAT、SOD、IRS-1、p-PI3K/PI3K及p-AKT/AKT水平均明显升高(P<0.05)、TG、TC、IL-6、TNF-α及MDA含量均显著降低(P<0.05),显示正常的肝实质。结论葛根芩连汤可明显改善胃肠湿热型2型糖尿病糖脂紊乱,可能是通过IRS-1/PI3K/AKT通路发挥作用。

基于Sentinel-1/2改进极化指数和纹理特征的土壤含盐量反演模型

目前Sentinel-1/2协同反演植被土壤含盐量的研究大多是基于Sentinel-2光谱信息和Sentinel-1后向散射系数,没有考虑Sentinel-2光谱信息容易受土壤亮度等信息影响,Sentinel-1后向散射系数容易受土壤粗糙度和水分影响。为进一步提高Sentinel-1/2协同反演植被土壤含盐量的精度,用水云模型对雷达卫星后向散射系数进行校正,消除植被影响;然后协同Sentinel-2纹理特征,基于VIP、OOB、PCA 3种变量筛选和RF、ELM、Cubist 3种机器学习回归模型构建植被土壤含盐量反演模型。研究结果表明:经过水云模型去除植被影响后的雷达后向散射系数及其极化组合指数与土壤含盐量的相关性有一定程度的提高。不同变量选择方法与不同机器学习方法耦合模型在反演土壤含盐量中,OOB变量筛选方法与RF、ELM和Cubist 3种机器学习方法的耦合模型精度最佳,建模集和验证集的R2都在0.750以上,且验证集的RMSE和MAE均最小;其中OOB-Cubist耦合模型精度最高,且R_(v)^(2)/R_(c)^(2)为0.955,具有良好的鲁棒性。研究可为机器学习协同物理模型、光学卫星协同雷达卫星在土壤含盐量反演中的进一步应用提供思路。

Keap1/Nrf2信号通路在非小细胞肺癌氧化应激机制中的作用

目的检测非小细胞肺癌(NSCLC)组织中Kelch样环氧氯丙烷相关蛋白-1(Keap1)、核因子E2相关因子2(Nrf2)蛋白表达水平,分析其与临床病理参数、氧化应激指标的相关性,为临床治疗提供潜在靶点。方法选取2017年4月至2020年4月郑州市第三人民医院收治的100例NSCLC患者为研究对象,免疫组化法检测并比较癌组织、癌旁组织中Keap1、Nrf2蛋白表达水平;比较不同临床病理参数患者Keap1、Nrf2蛋白表达水平;比较不同Keap1、Nrf2蛋白表达患者血清超氧化物歧化酶(SOD)、诱导型一氧化氮合酶(iNOS)、丙二醛(MDA)水平,并采用Spearman法分析SOD、i NOS、MDA与临床病理参数的相关性,采用Pearson法分析SOD、iNOS、MDA与Keap1、Nrf2蛋白水平的的相关性;比较不同Keap1、Nrf2蛋白表达患者的生存率。结果癌组织、癌旁组织Keap1蛋白阳性率分别为77.00%、53.00%,Nrf2蛋白阳性率分别为74.00%、45.00%,Keap1蛋白OD值分别为0.41±0.07、0.33±0.05,Nrf2蛋白OD值分别为0.39±0.06、0.31±0.06,癌组织Keap1、Nrf2蛋白阳性率及OD值明显高于癌旁组织,差异均有统计学意义(P<0.05);Keap1蛋白阳性表达与病理分级、T分期呈正相关(r=0.569、0.574,P<0.01),Nrf2蛋白阳性表达与病理分级、T分期呈正相关(r=0.527、0.539,P<0.01);Keap1蛋白阳性者、阴性者的血清SOD水平分别为(86.78±9.14)U/m L、(115.07±12.13)U/m L,MDA水平分别为(4.42±0.82)mmol/L、(3.24±0.56)mmol/L,i NOS水平分别为(22.74±4.31)U/m L、(15.59±3.02)U/mL,Nrf2蛋白阳性者、阴性者血清SOD水平分别为(84.94±9.12)U/mL、(117.06±12.37)U/mL,MDA水平分别为(4.48±0.85)mmol/L、(3.21±0.52)mmol/L,iNOS水平分别为(23.02±4.28)U/mL、(15.64±3.10)U/mL,Keap1、Nrf2蛋白阳性者血清SOD水平明显低于阴性者,MDA、iNOS水平明显高于阴性者,差异均有统计学意义(P<0.05);Keap1、Nrf2蛋白表达与SOD呈负相关(r=-0.612、-0.614,P<0.01),与MDA、iNOS呈正相关(r_(Keap1)=0.609、0.614,P<0.01;r_(Nrf2)=0.610、0.608,P<0.01);Keap1、Nrf2蛋白阳性表达者3年生存率为85.71%、83.78%,明显低于阴性表达者的95.65%、100.00%,差异均有统计学意义(P<0.05)。结论NSCLC组织中Keap1、Nrf2蛋白表达水平升高,且与病理分级、T分期密切相关,该信号通路活化可参与氧化应激反应过程,且对预判患者预后具有一定临床意义。

槲皮素预处理ALI大鼠肺组织损伤、炎症/氧化应激反应、铁死亡及Nrf2/HO-1信号通路激活情况观察

目的观察槲皮素灌胃预处理的LPS诱导急性肺损伤(ALI)大鼠肺组织损伤、炎症反应、氧化应激反应、铁死亡及Nrf2/HO-1信号通路激活情况,以探讨槲皮素对ALI的预防作用及机制。方法24只SD大鼠分为槲皮素低、中、高剂量组和阳性对照组(地塞米松)、模型组、正常对照组。槲皮素低、中、高剂量组以25、50、100 mg/kg槲皮素灌胃,1次/天,连续7 d;槲皮素灌胃处理的第4天在大鼠气管内滴注5 mg/kg LPS;阳性对照组以地塞米松1.04 mg/kg灌胃,其余处理同槲皮素组;模型组以生理盐水灌胃,1次/天,连续7天,其余处理同槲皮素组;正常对照组以生理盐水连续灌胃7 d。末次灌注给药后,观察各组肺组织损伤(肺功能及肺组织病理改变、纤维组织阳性表达率、肺泡上皮细胞凋亡率)、炎症反应(肺泡灌洗液TNF-α、IL-6、IL-1β)、氧化应激反应(肺泡灌洗液SOD、GSH、MDA,肺组织ROS)、铁死亡(Fe^(2+)水平)及Nrf2/HO-1信号通路激活[肺组织核因子红细胞2相关因子2(Nfr2)、血红素加氧酶1(HO-1)、超氧化物歧化酶2(SOD2)、过氧化氢酶(CAT)蛋白]情况。结果与正常对照组比较,模型组PaCO_(2)水平升高,PaO_(2)、SaO_(2)水平降低(P均<0.01);肺组织可见肺泡上皮细胞变性坏死,纤维组织阳性表达率高;肺泡上皮细胞凋亡率高;肺泡灌洗液中TNF-α、IL-6、IL-1β水平均升高,SOD、GSH水平降低,MDA水平升高,肺组织ROS表达水平升高,肺泡灌洗液中Fe^(2+)水平升高(P均<0.05)。与模型组相比,槲皮素中、高剂量组和阳性对照组中PaCO_(2)均降低(P均<0.05),槲皮素高剂量组PaO_(2)和SaO_(2)水平升高(P均<0.05);槲皮素高剂量组与阳性对照组肺组织炎性浸润与纤维增生明显减少,肺泡恢复正常生理结构;槲皮素低、中、高剂量组和阳性对照组肺纤维组织阳性表达率均下降(P均<0.05),其中槲皮素高剂量组肺纤维组织阳性表达率最低;槲皮素低、中、高剂量组和阳性对照组肺泡上皮细胞凋亡率均降低(P均<0.01);槲皮素低、中、高剂量组和阳性对照组肺泡灌洗液中TNF-α、IL-6、IL-1β水平均降低、SOD、GSH水平升高、MDA水平降低,肺组织ROS表达水平降低(P均<0.01),肺泡灌洗液中Fe^(2+)水平降低。与正常对照组比较,模型组肺组织中CAT、HO-1、Nrf2、SOD2蛋白表达水平低(P均<0.01);与模型组比较,槲皮素中、高剂量组和阳性对照组肺组织中CAT、HO-1、Nrf2、SOD2蛋白表达水平高(P均<0.05)。结论槲皮素灌胃预处理的ALI大鼠肺组织损伤、炎症反应、氧化应激反应、铁死亡情况减轻,Nfr2/HO-1信号通路激活;槲皮素灌胃预处理可预防LPS诱导的大鼠ALI,可能通过抑制炎症反应、氧化应激反应及铁死亡而起作用;槲皮素可能通过上调Nfr2/HO-1信号通路而抑制炎症反应、氧化应激反应及铁死亡;50、100 mg/kg槲皮素均对LPS诱导的大鼠ALI起预防作用,以100 mg/kg槲皮素的作用效果更佳。

多发性子宫肌瘤患者血清ANGPTL2、VASH1的表达及临床意义

目的 分析血清中血管生成素样蛋白2(ANGPTL2)和血管生成抑制蛋白1(VASH1)的表达水平,探讨其在多发性子宫肌瘤中的临床意义。方法 选取2018年1月至2022年1月于东南大学医学院附属南京同仁医院就诊的312例多发性子宫肌瘤患者为研究对象(观察组),同时期来本院体检的312名健康女性作为对照(对照组);酶联免疫吸附试验(ELISA)检测血清中ANGPTL2和VASH1水平;Pearson相关分析血清中ANGPTL2和VASH1水平的相关性;受试者工作特征(ROC)曲线分析血清中ANGPTL2和VASH1水平对多发性子宫肌瘤的诊断价值;Logistic回归分析多发性子宫肌瘤发生的影响因素。结果 观察组血清中ANGPTL2和VASH1水平显著高于对照组,差异有统计学意义(t=12.870、9.935,P<0.05);血清中ANGPTL2和VASH1水平与阴道不规则出血、肌瘤数量、最大肌瘤直径以及平均肌瘤体积有关,差异有统计学意义(P<0.05),而与年龄、月经情况、绝经情况、妊娠史、流产史、ER、PR以及肿瘤部位无关,差异无统计学意义(P>0.05);Pearson相关分析结果显示,多发性子宫肌瘤患者血清中ANGPTL2和VASH1水平呈正相关(r=5.440,P<0.05);ROC曲线分析结果显示,血清中ANGPTL2和VASH1水平联合诊断多发性子宫肌瘤的曲线下面积(AUC),效果较ANGPTL2和VASH1单一指标更好(P<0.05);Logistic回归分析结果显示,ANGPTL2、VASH1是多发性子宫肌瘤发生的影响因素(P<0.05)。结论 多发性子宫肌瘤患者血清中ANGPTL2和VASH1水平显著升高,两者联合可辅助诊断多发性子宫肌瘤。

WNK2通过抑制ERK1/2/ROS/SHP2信号通路延缓肝细胞癌的增殖和侵袭

目的探讨WNK2对肝细胞癌(hepatocellocellua carcinoma,HCC)中ERK1/2/ROS/SHP2信号通路的影响,并探讨其在HCC细胞增殖和迁移中的作用。方法将WNK2-mimic和sh-RNA WNK2以及相应的阴性对照转染HepG2细胞,采用BALB/c裸鼠皮下成瘤实验检测WNK2对肝细胞癌增殖能力的影响;采用Western Blot检测瘤组织中WNK2、p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达;使用SHP2抑制剂PHPS1进行处理之后,采用Western Blot检测HepG2细胞中WNK2、p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达;使用细胞划痕实验和Transwell检测HepG2细胞的迁移能力和侵袭能力;采用单克隆增殖实验和CCK-8检测HepG2细胞的增殖能力。结果与sh-NC组相比,sh-RNA WNK2组裸鼠的瘤体体积显著增大(P<0.01);而与NC-mimic组相比,WNK2-mimic组裸鼠的瘤体体积显著减小(P<0.01);Western Blot结果显示,与sh-NC组相比,sh-RNA WNK2组WNK2的表达显著降低(P<0.01),p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达显著升高(P<0.01);而与NC-mimic组相比,WNK2-mimic组WNK2的表达显著升高(P<0.01),p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达显著降低(P<0.01);在体外实验当中,相对于sh-NC组,sh-RNA WNK2组中WNK2的表达显著降低(P<0.01),p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达显著升高(P<0.01);相对于sh-NC+PHPS1组,sh-RNA WNK2+PHPS1组中WNK2的表达显著降低(P<0.01),而p40、gp90、p-SHP2、p-AKT和p-ERK1/2的表达则被逆转并且与sh-NC+PHPS1组不具有显著性差异(P>0.05);细胞划痕实验和Transwell结果显示,相对于sh-NC组,sh-RNA WNK2组HepG2细胞的迁移和侵袭能力显著升高(P<0.01);sh-NC+PHPS1组和sh-RNA WNK2+PHPS1组HepG2细胞的迁移和侵袭能力显著降低并且不具有显著性差异(P>0.05);单克隆增殖实验结果显示,相对于sh-NC组,sh-RNA WNK2组HepG2细胞的增殖能力显著升高(P<0.01),而sh-NC+PHPS1组和sh-RNA WNK2+PHPS1组HepG2细胞的增殖能力显著降低并且不具有显著性差异(P>0.05)。结论WNK2可以抑制ERK1/2/ROS/SHP2信号通路,从而抑制ERK1/2/AKT信号通路,延缓HCC的增殖和迁移。

人参皂苷Rg3通过调控E2F1对人胃癌SGC-7901细胞生物行为学的影响

目的探究人参皂苷Rg3通过调控E2F1对人胃癌SGC-7901细胞生物行为学的影响。方法MTT测定不同浓度人参皂苷Rg3(0、80、160、320μmol·L^(-1))对细胞增殖影响;流式细胞术测定不同浓度人参皂苷Rg3对细胞凋亡的影响;划痕愈合实验和Transwell实验测定不同浓度人参皂苷Rg3对细胞迁移及侵袭的影响;Western blot测定不同浓度人参皂苷Rg3对E2F1、MMP-2、MMP-9、BCL-2、Bax表达的影响。结果80、160、320μmol·L^(-1)人参皂苷Rg3组细胞存活率与空白对照组比较明显降低,且呈浓度依赖性(P<0.05)。80、160、320μmol·L^(-1)人参皂苷Rg3组细胞凋亡率与空白对照组比较明显增加,且呈浓度依赖性(P<0.05)。80、160、320μmol·L^(-1)人参皂苷Rg3组细胞迁移数目与空白对照组比较明显降低,且呈浓度依赖性(P<0.05)。80、160、320μmol·L^(-1)人参皂苷Rg3组细胞侵袭数目与空白对照组比较明显降低,且呈浓度依赖性(P<0.05)。80、160、320μmol·L^(-1)人参皂苷Rg3组E2F1 mRNA与E2F1蛋白表达量相较空白对照组明显减少且,呈浓度依赖性(P<0.05)。80、160、320μmol·L^(-1)人参皂苷Rg3组细胞中MMP-2、MMP-9、BCL-2蛋白表达量与空白对照组比较明显降低,BCL-2与空白对照组比较明显升高,且呈浓度依赖性(P<0.05)。结论人参皂苷Rg3能降低胃癌SGC-7901细胞增殖能力,抑制细胞迁移及侵袭能力,同时还促进SGC-7901细胞凋亡,且具有浓度依赖性,其作用机制可能通过E2F1因子下调MMP-2、MMP-9、BCL-2表达,上调Bax表达有关。

常压高浓度氧对新生大鼠脑微血管内皮细胞损伤与Nrf2/HO-1信号通路的影响分析

目的探究常压高浓度氧(NBO)对新生大鼠脑微血管内皮细胞损伤及核因子E2相关因子2/血红素氧合酶-1(Nrf2/HO-1)信号通路的影响。方法取新生SD大鼠45只,采用随机数字表法分为常氧组、NBO组和NBO+Nrf2激活剂组,每组各15只。常氧组大鼠置于普通空气(21%氧气)中饲养,NBO组和NBO+Nrf2激活剂组大鼠置于90%常压氧气饲养,NBO+Nrf2激活剂组每日灌胃5 mg/kg Nrf2激动剂莱菔硫烷。测定脑组织伊文思蓝(EB)含量,采用酶联免疫法检测血管内皮生长因子(VEGF)和基质金属蛋白酶9(MMP-9)含量,干湿重法检测脑组织含水量,HE染色和TUNEL染色观察脑组织病理变化,蛋白质印迹法检测海马组织Nrf2/HO-1信号通路蛋白表达,水迷宫检测大鼠认知功能。结果与常氧组比较,NBO组脑组织EB、VEGF、MMP-9含量及脑组织含水量升高,差异均有统计学意义(P<0.05);与NBO组比较,NBO+Nrf2激活剂组脑组织EB、VEGF、MMP-9含量及脑组织含水量降低,差异均有统计学意义(P<0.05)。病理染色结果显示,常氧组大鼠神经细胞形态及结构完整,未见明显病理变化和细胞凋亡;NBO组神经细胞形态及结构不规则,出现明显的水肿和空泡,并伴有大量的凋亡细胞;NBO+Nrf2激活剂组脑组织病理损伤较NBO组明显减轻。与常氧组比较,NBO组脑组织Nrf2、HO-1蛋白相对表达量降低,差异均有统计学意义(P<0.05);与NBO组比较,NBO+Nrf2激活剂组Nrf2、HO-1蛋白相对表达量升高,差异均有统计学意义(P<0.05)。与常氧组比较,NBO组第2~4天逃避潜伏期延长,穿越平台次数减少,差异均有统计学意义(P<0.05);与NBO组比较,NBO+Nrf2激活剂组第2~4天逃避潜伏期缩短,穿越平台次数增多,差异均有统计学意义(P<0.05)。结论NBO可诱导新生大鼠脑微血管内皮细胞损伤,导致远期认知功能障碍,可能与下调Nrf2/HO-1信号通路表达有关。

不同年龄段婴儿1177例维生素K1与K2水平分布调查分析

目的探讨对比各年龄段婴儿血清维生素K1与K2水平,了解维生素K1与K2在不同年龄段婴儿体内的分布情况。方法选取课题单位(儿科、新生儿科、儿童保健科、产科)出生/就诊的儿童作为研究对象,按年龄为0~3 d(591例)、4~7 d(255例)、8~15 d(104例)、1个月(118例)、2个月(40例)、3个月(69例)进行分组。收集患者的一般资料,采用统一平台的高效液相色谱-质谱(LC-MS)法测定患者血清维生素K1与K2水平,从维生素K1与K2不同年龄段的水平分布,缺乏率进行数据分析。结果各年龄段的维生素K1与K2水平分布具有统计学意义(P<0.001);新生儿极易缺乏维生素K1,随着年龄增长,维生素K2的缺乏率高于维生素K1。结论维持维生素K1及K2的正常对于各年龄段婴幼儿的正常生长发育至关重要,应当密切关注婴幼儿维生素K1及K2的监测和补充。

黄芩苷对干酵母致热大鼠的解热作用及血清TNF-α、IL-1β、IL-6、PGE_(2)、cAMP和脑组织NF-κB表达的影响

目的:观察黄芩苷对干酵母致热大鼠的解热作用并探讨其作用机制。方法:采用背部皮下注射干酵母构建大鼠发热模型,SD雄性大鼠随机分为正常对照,模型组,阳性组(阿司匹林,0.1 g/kg),黄芩苷高、中、低剂量组(160、80、40 mg/kg),连续给药3 d,测定各组大鼠肛温的变化;酶联免疫法(ELISA)检测血清肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)、白细胞介素-6(IL-6)、前列腺素E_(2)(PGE_(2))与环磷酸腺苷(cAMP)水平;Western Blot检测各组大鼠脑组织NF-κB p65(核转录因子-κB p65)蛋白表达。结果:黄芩苷高剂量组有显著解热效果(P<0.01),黄芩苷各剂量组均可不同程度降低大鼠血清TNF-α、IL-1β、IL-6、PGE 2和cAMP含量;与正常组比较,模型组脑组织NF-κB p65蛋白表达增多,黄芩苷高剂量组可明显降低大鼠脑组织NF-κB p65表达(P<0.05)。结论:黄芩苷可显著性降低干酵母引起的体温升高,解热机制可能与抑制TNF-α、IL-1β、IL-6、PGE_(2)与cAMP的分泌和减少脑组织NF-κB p65蛋白表达有关。

IL-1β通过激活ERK1/2信号通路抑制人脐带间充质干细胞CD200表达抑制巨噬细胞M2极化

目的探究白细胞介素1β(IL-1β)调控人脐带间充质干细胞CD200表达及其对巨噬细胞极化的影响及作用机制。方法无血清培养基分离培养获得人脐带间充质干细胞(hUC-MSC),形态学观察及流式细胞术检测CD73、CD90、CD105、CD14、CD34、CD45、人类白细胞抗原DR(HLA-DR)的表达,确定间充质干细胞属性;20 ng/mL IL-1β处理hUC-MSC 24 h,流式细胞术检测CD200阳性细胞率,实时定量PCR和Western blot法检测CD200 mRNA和蛋白表达水平;佛波酯(PMA)诱导THP-1巨噬细胞活化,并与IL-1β处理感染CD200过表达慢病毒的hUC-MSC共培养,流式细胞术检测CD11c和CD206阳性细胞比例;IL-1β联合细胞外信号调节激酶1/2(ERK1/2)特异性抑制剂PD98059处理hUC-MSC,Western blot法检测细胞丝裂原激活蛋白激酶(MAPK)信号分子与CD200的表达。结果IL-1β显著下调hUC-MSC CD200蛋白表达与CD200阳性细胞率;过表达CD200显著上调hUC-MSC CD200表达,且CD200过表达hUC-MSC提高巨噬细胞CD206阳性细胞比率;IL-1β激活hUC-MSC的ERK1/2信号通路,PD98059上调IL-1β处理后hUC-MSC中CD200的蛋白表达。结论IL-1β通过激活ERK1/2信号通路抑制CD200的表达,进而抑制hUC-MSC对巨噬细胞向M2型极化的促进作用。